CL-82198

CL-82198 is a selective inhibitor of MMP-13. CL-82198 binds to the entire S1’ pocket of MMP-13, which is the basis for its selectivity towards MMP-13 and the lack of inhibitory activities against other MMPs[1][2]. CL-82198 is a pharmacologic treatment for preventing osteoarthritis (OA) progression[4].

Product Specifications

CAS Number

[307002-71-7]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

MMP

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/CL-82198.html

Concentration

10mM

Purity

99.71

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=CC2=CC=CC=C2O1)NCCCCN3CCOCC3

Molecular Formula

C17H22N2O3

Molecular Weight

302.37

Precautions

H302, H315, H319, H335

References & Citations

[1]Rath T et al. Matrix metalloproteinase-13 is regulated by toll-like receptor-9 in colorectal cancer cells and mediates cellular migration. Oncol Lett. 2011 May;2 (3) :483-488.|[2]Wohlauer M et al. Nebulized hypertonic saline attenuates acute lung injury following trauma and hemorrhagic shock via inhibition of matrix metalloproteinase-13. Crit Care Med. 2012 Sep;40 (9) :2647-53.|[3]George J, et al. MMP-13 deletion decreases profibrogenic molecules and attenuates N-nitrosodimethylamine-induced liver injury and fibrosis in mice. J Cell Mol Med. 2017 Dec;21 (12) :3821-3835.|[4]Wang M, et al. MMP13 is a critical target gene during the progression of osteoarthritis. Arthritis Res Ther. 2013 Jan 8;15 (1) :R5.